title: Volume control in peritoneal dialysis patients: role of new dialysis solutions.
abstract: This paper reviews the most recent clinical data on the volume status of long-term peritoneal dialysis (PD) patients. It appears that many PD patients are volume overloaded, associated with a high prevalence of hypertension and left ventricular hypertrophy. In the presence of the poor results in patients with peritoneal ultrafiltration, the introduction of the polyglucose solution, icodextrin, has ameliorated volume control in some of these patients. In a second part of the review, some of the structural and functional alterations in the peritoneal membrane and the role of glucose degradation products (GDP) in the commonly used dialysates as well as the resulting formation of advanced glycation end products are described. The introduction of low GDP-containing solutions at normal pH has at least in experimental models of PD attenuated the hemodynamic changes observed with the classical solutions. The solutions at normal pH containing either bicarbonate or a mixture of bicarbonate/lactate were clinically associated with less inflow pain.
authors.affiliation: Renal Division, University Hospital, Ghent, Belgium. norbert.lameire@ugent.be
authors.forename: Norbert
authors.initials: N
authors.lastname: Lameire
mesh_terms: D000138:Acidosis / Q000209:etiology / Q000517:prevention & control; D001639:Bicarbonates / Q000008:administration & dosage; D001810:Blood Volume / Q000187:drug effects*; D004311:Double-Blind Method; D005936:Glucans / Q000008:administration & dosage*; D005947:Glucose / Q000008:administration & dosage* / Q000009:adverse effects; D017127:Glycation End Products, Advanced / Q000032:analysis; D015312:Hemodialysis Solutions / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control*; D017379:Hypertrophy, Left Ventricular / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control*; D000077607:Icodextrin; D007676:Kidney Failure, Chronic / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D007773:Lactates / Q000008:administration & dosage / Q000009:adverse effects; D015337:Multicenter Studies as Topic; D010146:Pain / Q000139:chemically induced / Q000209:etiology; D010530:Peritoneal Dialysis / Q000009:adverse effects / Q000379:methods*; D010538:Peritonitis / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D012964:Sodium / Q000008:administration & dosage / Q000009:adverse effects; D017211:Treatment Failure
chemical_list: D001639:Bicarbonates; D005936:Glucans; D017127:Glycation End Products, Advanced; D015312:Hemodialysis Solutions; D007773:Lactates; D000077607:Icodextrin; D012964:Sodium; D005947:Glucose